Gastroenterology
Volume 137, Issue 5 , Pages 1680-1686 , November 2009

Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States

  • W. Ray Kim

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • Corresponding Author InformationReprint requests Address requests for reprints to: W. Ray Kim, MD, Division of Gastroenterology and Hepatology (PL 6), 200 1st Street SW, Rochester, Minnesota 55905. fax: (507) 538-3974
    • ,
  • Norah A. Terrault

      Affiliations

    • University of California-San Francisco, San Francisco, California
    • ,
  • Rachel A. Pedersen

      Affiliations

    • Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Terry M. Therneau

      Affiliations

    • Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Erick Edwards

      Affiliations

    • United Network for Organ Sharing, Richmond, Virginia
    • ,
  • Andrew A. Hindman

      Affiliations

    • Gilead Sciences, Inc, Foster City, California
    • ,
  • Carol L. Brosgart

      Affiliations

    • Gilead Sciences, Inc, Foster City, California

References 

  1. Kim WR, Brown RS, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242
  2. Kim WR, Benson JT, Therneau TM, et al. Changing epidemiology of hepatitis B in a US community. Hepatology. 2004;39:811–816
  3. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714
  4. Davis G, Albright J, Cook S, et al. Projecting the future healthcare burden from hepatitis C in the United States (abstr). Hepatology. 1998;28:390A
  5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  6. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–823
  7. Dienstag J, Schiff E, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–1263
  8. Marcellin J, Chang T-T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;384:808–816
  9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807
  10. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
  11. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020
  12. Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  13. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455
  14. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  15. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplantation. 2002;8:433–439
  16. Schiff ER, Lai C-L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003;38:1419–1427
  17. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  19. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000;32:1131–1137
  20. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587
  21. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver D Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  22. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10:968–974
  23. Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997;3:628–637
  24. Kamath PS, Kim WR. Model for End-stage Liver Disease (MELD). Hepatology. 2007;45:797–805
  25. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127(5 Suppl 1):S261–S267
  26. Welch S, Chiang B, Shadday P, et al. Estimated prevalence of chronic hepatitis B in foreign-born persons living in the United States by country/region of origin (abstr). Hepatology. 2008;48:687A
  27. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134–1144
  28. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117
  29. Alter M, Moran-Kruszon D, Nainan O, et al. The prevalence of hepatitis C virus infection in the United States. N Engl J Med. 1994;341:556–562
  30. Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology. 2008;47:1128–1135
  31. Anonymous. Hepatitis surveillance report 61. Atlanta, GA: Centers for Disease Control and Prevention; 2006;
  32. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459–2463
  33. Lee WM, Squires RH, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415

 Conflicts of interest The authors disclose the following: W. Ray Kim received a grant from the Gilead Sciences, Inc, to conduct this study. He has served as a consultant for Roche, Bristol–Myers–Squibb, Idenix, Schering-Plough, and Gilead Sciences. Norah Terrault has received grants from Gilead Sciences, Cangene, NABI, and Roche and consulted Bristol-Myers-Squibb. Andrew Hindman was a former employee of Gilead Sciences, Inc, and Carol Brosgart was a former employee of Gilead Sciences. Terry Therneau, Rachel Pedersen, and Erick Edwards disclose no conflicts.

 Funding Supported by grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK-34238 and DK-61617), and Gilead Sciences, Inc, provided unrestricted grant in partial support of the work; however, the content of the work including data analysis and interpretation was solely that of the authors.

PII: S0016-5085(09)01246-3

doi: 10.1053/j.gastro.2009.07.047

Gastroenterology
Volume 137, Issue 5 , Pages 1680-1686 , November 2009

Article Tools

* Image Usage & Resolution